These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 24666499)

  • 1. [Observation of low-dose HA/HAA regimen as induction chemotherapy on elderly patients with acute myeloid leukemia].
    Wu D; Ye B; Shen J; Shen Y; Lin S; Hu Z; Yu Q; Zheng Z; Peng L; Liu S; Ji C; Luo Y; Wen X; Shao K; Zhang Y; Gao Y; Chen D; Zhou Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):256-9. PubMed ID: 24666499
    [No Abstract]   [Full Text] [Related]  

  • 2. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
    Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
    Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Low-dose ARA-C and HOAAP regimen in the treatment of adult acute nonlymphocytic leukemia: analysis of 59 cases].
    Dong ZR; Yao EG; Xu SR
    Zhonghua Nei Ke Za Zhi; 1988 May; 27(5):300-2, 327. PubMed ID: 3197499
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
    Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
    Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curative effect of harringtonine semisynthetic harringtonine and HOAP on nonlymphocytic leukemias. Analysis of 304 cases.
    Zhang ZY; Hou CH; Zhu YF; You XY; Li JL; Fu Z
    Chin Med J (Engl); 1987 Jul; 100(7):565-8. PubMed ID: 3123163
    [No Abstract]   [Full Text] [Related]  

  • 6. Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia.
    Jin J; Jiang DZ; Mai WY; Meng HT; Qian WB; Tong HY; Huang J; Mao LP; Tong Y; Wang L; Chen ZM; Xu WL
    Leukemia; 2006 Aug; 20(8):1361-7. PubMed ID: 16791270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage therapy with endostatin, low-dose homoharringtonine, and cytarabine in combination with granulocyte-colony stimulating factor for elderly patients with primary refractory acute myeloid leukemia.
    Fang B; Liu Y; Zhou J; Li Y; Song Y
    Am J Hematol; 2012 Jan; 87(1):126-7. PubMed ID: 22072502
    [No Abstract]   [Full Text] [Related]  

  • 8. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial.
    Jin J; Wang JX; Chen FF; Wu DP; Hu J; Zhou JF; Hu JD; Wang JM; Li JY; Huang XJ; Ma J; Ji CY; Xu XP; Yu K; Ren HY; Zhou YH; Tong Y; Lou YJ; Ni WM; Tong HY; Wang HF; Mi YC; Du X; Chen BA; Shen Y; Chen Z; Chen SJ
    Lancet Oncol; 2013 Jun; 14(7):599-608. PubMed ID: 23664707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose homoharringtonine versus standard-dose daunorubicin is effective and safe as induction and post-induction chemotherapy for elderly patients with acute myeloid leukemia: a multicenter experience from China.
    Huang BT; Zeng QC; Yu J; Liu XL; Xiao Z; Zhu HQ
    Med Oncol; 2012 Mar; 29(1):251-9. PubMed ID: 21258877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A homoharringtonine-based regimen for childhood acute myelogenous leukemia.
    Tang J; Xue H; Pan C; Chen J; Gu L; Zhao H
    Med Pediatr Oncol; 2003 Jul; 41(1):70-2. PubMed ID: 12764750
    [No Abstract]   [Full Text] [Related]  

  • 12. The priming induction regimen of HAG as a low dose chemotherapy strategy in AML clonal evolution.
    Chen A; Yang J; Hu S; Wang QF
    Sci China Life Sci; 2015 Dec; 58(12):1302-5. PubMed ID: 26588914
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
    Mi YC; Xue YP; Yu WJ; Liu SH; Zhao YZ; Meng QX; Bian SG; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2005 Dec; 26(12):705-9. PubMed ID: 16620570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HOAP/HOAGP in the treatment of acute non-lymphocytic leukemia: an analysis of 68 cases].
    Shan YD
    Zhonghua Yi Xue Za Zhi; 1985 Oct; 65(10):590-2. PubMed ID: 3938671
    [No Abstract]   [Full Text] [Related]  

  • 15. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia.
    Feldman E; Arlin Z; Ahmed T; Mittelman A; Puccio C; Chun H; Cook P; Baskind P
    Leukemia; 1992 Nov; 6(11):1189-91. PubMed ID: 1434803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.
    Low M; Lee D; Coutsouvelis J; Patil S; Opat S; Walker P; Schwarer A; Salem H; Avery S; Spencer A; Wei A
    Intern Med J; 2013 Mar; 43(3):294-7. PubMed ID: 22757980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic effect of priming induction regimen of CAG for newly diagnosed acute myeloid leukemia in elderly patients].
    Chen YJ; Zhang LQ; Li XL; Zhao XL; Wu DS; Shu YG; Chen FP
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Mar; 33(3):245-51. PubMed ID: 18382060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are adjuncts to induction chemotherapy worthwhile in the treatment of acute myeloid leukemia?
    Ravandi F
    Best Pract Res Clin Haematol; 2014; 27(3-4):241-6. PubMed ID: 25455273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis on prognosis and correlative factors of acute nonlymphocytic leukemia].
    Liu CY; Fu R; Liu WH; Cheng YQ; Song WX; DU LJ; Ruan EB; Zhang LT; Wang XM; Liang Y; Wang GJ; Qu W; Song J; Zhang RL; Guan J; Li LJ; Song Y; Gao S; Liu H; Jiang HJ; Wang J; Zou P; Shao ZH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1300-4. PubMed ID: 18088489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of the therapeutic efficacy and prognostic factors of intensive chemotherapy in 91 patients with acute nonlymphoblastic leukemia].
    Bian SG; Hao YS; Wang ZC
    Zhonghua Nei Ke Za Zhi; 1990 Jan; 29(1):22-5, 60. PubMed ID: 2401166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.